Clinical characteristics stratified by insurance type
| . | Medicare . | Medicaid . | Private . | Self-pay . | P value . |
|---|---|---|---|---|---|
| Median follow-up time (mo), median, (range) | 12.7 (0.3-69.3) | 7.3 (0.6-38.6) | 12.5 (0.2-60.0) | 8.7 (0.1-19.2) | .161 |
| Age (y), median (range) | 64.0 (22.0-84.0) | 52.5 (22.0-61.0) | 56.0 (25.0-84.0) | 56.0 (22.0-74.0) | <.001 |
| Prior lines of therapy, median (range) | 2.0 (1.0-6.0) | 3.0 (1.0-6.0) | 2.0 (1.0-6.0) | 2.0 (2.0-3.0) | .814 |
| CAR-T therapy timing | |||||
| Second line, n (%) | 73 (37) | 13 (41) | 88 (42) | 4 (57) | .9 |
| Third line and beyond, n (%) | 90 (46) | 18 (56%) | 96 (46) | 1 (14) | |
| Time from diagnosis to CAR-T infusion, mo (range) | 26.2 (1.6-383.7) | 14.4 (5.2-113.3) | 14.0 (2.0-440.0) | 14.5 (10.2-185.4) | .001 |
| Time from progression to CAR-T infusion, mo (range) | 2.0 (0.0-61.0) | 1.7 (0.4-12.5) | 2.0 (0.2-61.0) | 3.2 (1.1-56.8) | .067 |
| Time from apheresis to CAR-T infusion, mo (range) | 1.1 (0.2-12.7) | 1.1 (0.6-5.1) | 1.1 (0.2-8.2) | 1.1 (0.8-4.6) | .417 |
| Bridging therapy, n (%) | 78 (39.8%) | 15 (46.9%) | 105 (50.0%) | 2 (28.6%) | .166 |
| Elevated LDH at apheresis, n (%) | 98 (68.1%) | 15 (71.4%) | 107 (66.9%) | 4 (66.7%) | .978 |
| . | Medicare . | Medicaid . | Private . | Self-pay . | P value . |
|---|---|---|---|---|---|
| Median follow-up time (mo), median, (range) | 12.7 (0.3-69.3) | 7.3 (0.6-38.6) | 12.5 (0.2-60.0) | 8.7 (0.1-19.2) | .161 |
| Age (y), median (range) | 64.0 (22.0-84.0) | 52.5 (22.0-61.0) | 56.0 (25.0-84.0) | 56.0 (22.0-74.0) | <.001 |
| Prior lines of therapy, median (range) | 2.0 (1.0-6.0) | 3.0 (1.0-6.0) | 2.0 (1.0-6.0) | 2.0 (2.0-3.0) | .814 |
| CAR-T therapy timing | |||||
| Second line, n (%) | 73 (37) | 13 (41) | 88 (42) | 4 (57) | .9 |
| Third line and beyond, n (%) | 90 (46) | 18 (56%) | 96 (46) | 1 (14) | |
| Time from diagnosis to CAR-T infusion, mo (range) | 26.2 (1.6-383.7) | 14.4 (5.2-113.3) | 14.0 (2.0-440.0) | 14.5 (10.2-185.4) | .001 |
| Time from progression to CAR-T infusion, mo (range) | 2.0 (0.0-61.0) | 1.7 (0.4-12.5) | 2.0 (0.2-61.0) | 3.2 (1.1-56.8) | .067 |
| Time from apheresis to CAR-T infusion, mo (range) | 1.1 (0.2-12.7) | 1.1 (0.6-5.1) | 1.1 (0.2-8.2) | 1.1 (0.8-4.6) | .417 |
| Bridging therapy, n (%) | 78 (39.8%) | 15 (46.9%) | 105 (50.0%) | 2 (28.6%) | .166 |
| Elevated LDH at apheresis, n (%) | 98 (68.1%) | 15 (71.4%) | 107 (66.9%) | 4 (66.7%) | .978 |